Adverse Events, Treatment Burden, and Outcomes of Intravenous versus Intra-arterial Chemotherapy for Retinoblastoma
Pranav R. Santapuram, Emma Schremp, Debra L. Friedman, Tatsuki Koyama, Michael T. Froehler, Anthony B. Daniels
Abstract
ABSTRACT This pilot retrospective study compares ocular outcomes, adverse events, and treatment burden for 114 treatment cycles (67 IVC, 47 IAC) for 19 patients receiving intra-arterial (IAC) or intravenous chemoreduction (IVC) for retinoblastoma. IAC patients had fewer unplanned health care visits (p=0.012), fewer grade 3/4 cytopenias (p
Topics & Concepts
MedicineAdverse effectRetinoblastomaRetrospective cohort studyChemotherapySurgeryInternal medicineGeneBiochemistryChemistryOcular Oncology and TreatmentsEar and Head TumorsBrain Metastases and Treatment